PhaseBio Pharmaceuticals, Inc.
PHAS · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $77 | $98 | $168 | $16 |
| - Cash | $42 | $28 | $74 | $61 |
| + Debt | $8 | $12 | $15 | $8 |
| Enterprise Value | $43 | $82 | $109 | -$37 |
| Revenue | $0 | $0 | $2 | $1 |
| % Growth | -96.6% | -86.4% | 253.4% | – |
| Gross Profit | $0 | $0 | $2 | $1 |
| % Margin | 100% | 0.1% | 100% | 100% |
| EBITDA | $2 | -$97 | -$38 | -$20 |
| % Margin | 15,350.2% | -30,191.3% | -1,609.4% | -2,966.6% |
| Net Income | -$0 | -$99 | -$39 | -$24 |
| % Margin | -1,210.1% | -30,801.6% | -1,662.3% | -3,569.8% |
| EPS Diluted | -0.005 | -3.39 | -1.43 | -4.49 |
| % Growth | 99.9% | -137.1% | 68.2% | – |
| Operating Cash Flow | -$47 | -$60 | -$40 | -$17 |
| Capital Expenditures | -$3 | -$1 | -$1 | -$0 |
| Free Cash Flow | -$50 | -$61 | -$41 | -$17 |